Dyadic International, Inc. (DYAI) stock announced that it has entered into the COVID-19 vaccine technology  Transfer and Licensing agreement(Rubic agreement) with Rubic Consortium after which the DYAI stock price saw a push of 57.56% to reach $5.42 a share at the time of this writing. The stock was gloomy in the previous trading session and went down by 3.64% at closing. Let’s deep dive to explore more of it.

Recent Activity of DYAI stock:

Dyadic International, Inc is the biotechnology stock engaged in the development, production, and selling of enzymes and other proteins in the United States. DYAI stock announced Transfer and Licensing agreement with Rubic Consortium which is the South African-based company striving for the discovery, development, and manufacturing of cost-effective and high-quality vaccines for the country. The highlights of the Rubic agreement are as follows.

Rubic Agreement:

• Rubic will get the license to use the C1 platform for various operations related to the COVID-19 vaccine in which development, manufacturing, and regulatory approval are also included.
• Rubic will present the phase proposed design of the phase II clinical trial and will be responsible for the funding in a specific period.
• Following specific rules and regulations, Rubic will be able to use the C1 platform to conduct research and development, pre-clinical and clinical studies, and commercialization of Covid-19 vaccines along with other vaccines.
• Dyadic stock will facilitate the technology transfer to Rubic until the completion of clinical trials.
• DYAI stock will have the right to use, sell, market, and commercialize COVID-19 products that will be formed via joint development with Rubic.
• DYAI stock will also provide some other technical tools and assistance to the Rubic in addition to C1-cells that are genetically modified and engineered.

Previous news of DYAI stock:

About a month ago, DYAI stock did announce that its C1-cell protein production platform was considered as the rapid response platform for the manufacturing of vaccines against zoonotic diseases. The platform showed SBV antigen exhibited potency, efficacy, and safety in veterinary target species. The antigens in the platform were successful in developing the recombinant particle-display vaccines

Conclusion:

Investors are responding positively to the recent announcement by the DYAI stock today. Though this stock is progressing with time but deep fundamental, as well as technical analysis, is necessary before adding this stock to the portfolio.